Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

399.34 +0.53 (+0.13%)
Streaming Delayed Price Updated: 9:35 AM EDT, May 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Argenx Se ADR

< Previous 1 2 3 4 5 6 7 Next >
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic... 
Via Talk Markets
FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults
The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or... 
Via Benzinga
AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease
The European Union has reco 
Via Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult... 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
The Latest Analyst Ratings for argenx
Via Benzinga
Analyst Expectations for argenx's Future
Via Benzinga
Expert Ratings for argenx
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 31, 2023
Via Benzinga
Booking Holdings To Rally Around 18%? Here Are 10 Other Analyst Forecasts For Friday
Wells Fargo raised the price target for Royal Caribbean Cruises Ltd. (NYSE: RCL) from $78 to $88. Wells Fargo analyst Daniel Politzer maintained an Overweight rating. Royal Caribbean Cruises shares... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
A Bearish Sign Appears On argenx's Chart
Via Benzinga
7 Biotech Stocks That Could Cure Your Portfolio Woes
If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment
Via Benzinga
5 Analysts Have This to Say About argenx
Via Benzinga
Earnings Outlook For argenx
Via Benzinga
Immunovant Could Potentially Be An M&A Target, Writes Analyst
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
Expert Ratings for argenx
Via Benzinga
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
AT&T To Rally Over 15%? Here Are 10 Other Analyst Forecasts For Tuesday
Keybanc boosted Five Below, Inc. (NASDAQ: FIVE) price target from $188 to $200. Keybanc analyst Bradley Thomas maintained an Overweight rating on the stock. Five Below shares fell 1.6% to $183.92 in... 
Via Benzinga
Alphabet To $115? Here Are 10 Other Price Target Changes For Thursday
Stifel raised argenx SE (NASDAQ: ARGX) price target from $471 to $478. Stifel analyst Alex Thompson maintained a Buy rating on the stock. argenx shares rose 1.1% to $387.07 in pre-market trading. 
Via Benzinga
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 108 stocks hit new 52-week highs. 
Via Benzinga
Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
Via Benzinga
McDonald's To Rally Over 13%? Here Are 5 Other Price Target Changes For Friday
Wedbush raised McDonald's Corporation (NYSE: MCD) price target from $265 to $300. Wedbush analyst Nick Setyan maintained the stock with an Outperform rating. McDonald's shares rose 3.3% to close at... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.